Tockman M S
Molecular Screening Program, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa 33612-9497, USA.
Cancer Control. 2000 Jan-Feb;7(1):19-24. doi: 10.1177/107327480000700101.
Screening for lung cancer using currently available techniques is not effective in reducing mortality from the disease.
Archived sputum specimens and clinical data linking specimens to lung cancer outcomes from prior screening programs have been reexamined to evaluate altered gene expressing, including specific oncogene activation and tumor suppressor gene deletion, as well as genomic instability and abnormal methylation.
Several of these tests allow determination of a molecular diagnosis of cancer years before clinical presentation.
These sputum tests provide an impetus to reconsider screening for lung cancer. Prospective trials are required to confirm test performance characteristics, and management and intervention strategies must be developed that are appropriate to the stage at which lung cancer is diagnosed.
使用现有技术筛查肺癌并不能有效降低该疾病的死亡率。
对存档的痰液标本以及将标本与既往筛查项目的肺癌结局相关联的临床数据进行重新检查，以评估基因表达改变，包括特定癌基因激活和肿瘤抑制基因缺失，以及基因组不稳定性和异常甲基化。
其中一些检测能够在临床症状出现前数年确定癌症的分子诊断。
这些痰液检测促使人们重新考虑肺癌筛查。需要进行前瞻性试验以确认检测性能特征，并且必须制定适合肺癌诊断阶段的管理和干预策略。
